| Talk code | Title | Presenting Author |
|---|---|---|
| PO001 | A NOVEL CHROMOGENIC METHOD FOR MEASURING FACTOR VIII ACTIVITY IN THE PRESENCE OF THE BISPECIFIC ANTIBODY EMICIZUMAB | Alfred Weber |
| PO002 | ACQUIRED FACTOR X DEFICIENCY IN A PATIENT WITH MULTIPLE MYELOMA WITHOUT ASSOCIATED AMYLOIDOSIS. | Marina De la Torre de LA Paz |
| PO003 | ACQUIRED HEMOPHILIA : A PRESENTING AS GROSS HEMATURIA WITH FATAL OUTCOME | Nesrin Bensaid |
| PO004 | ASSESSING FACTOR VIII ACTIVITY IN THE PRESENCE OF MIM8 VIA CHROMOGENIC ASSAYS | William Pickering |
| PO005 | DOSE OPTIMISATION AND RISK MITIGATION DURING CONCIZUMAB PROPHYLAXIS IN PATIENTS WITH HAEMOPHILIA A/B WITH AND WITHOUT INHIBITORS IN PHASE 3 CLINICAL TRIALS | Pratima Chowdary |
| PO006 | EFFECT OF PLASMA-DERIVED FACTOR VIII/VON WILLEBRAND FACTOR IN PATIENTS WITH SEVERE HEMOPHILIA A ON PROPHYLAXIS WITH EMICIZUMAB: AN EX VIVO EVALUATION WITH A THROMBIN GENERATION ASSAY | Maria-Isabel Bravo |
| PO007 | IMPACT OF ANTITHROMBIN REDUCTION IN PLASMA ON COAGULATION ASSAYS | Ekta Seth Chhabra |
| PO008 | INDUCTION OF NEONATAL FC RECEPTOR-MEDIATED TOLERANCE TO THERAPEUTIC FACTOR VIII IN HEMOPHILIA A | Alejandra Reyes-Ruiz |
| PO009 | INDUCTION OF TOLERANCE TO THERAPEUTIC FACTOR VIII IN HA BY MODIFICATION WITH A2,3 SIALIC ACID | Eleonora Nardini |
| PO010 | LIVER SINUSOIDAL CELLS AS A NEW TARGET FOR TOLERANCE INDUCTION TO FVIII | Michela Leoni |
| PO011 | MUTATION ANALYSIS OF COHORT OF RUSSIAN PATIENTS WITH HEMOPHILIA A | Valentina Salomashkina |
| PO012 | ONE STAGE CHRONOMETRIC FVIII ASSAY OR TWO STAGE CHROMOGENIC FVIII ASSAY TO DIAGNOSE HAEMOPHILIA A? | Birgit Frotscher |
| PO013 | POST-INFUSION MONITORING OF FVIII REPLACEMENT THERAPY DATA FROM THE UK NEQAS BC EQA PROGRAMME 2021. | Christopher Reilly-Stitt |
| PO014 | POTENTIAL USE OF FIX CONCENTRATES TO REGULATE THE PROCOAGULANT EFFECT OF EMICIZUMAB | Elena Arias-Salgado |
| PO016 | SELECTION OF THE METHOD OF DETERMINATION THE ACTIVITY OF THE FACTOR VIII BLOOD COAGULATION WITH THE APPLICATION OF VIRUS-INACTIVATING AGENTS | Nataliia Shurko |
| PO017 | THIRD-GENERATION FVIII-SPECIFIC CAR CONSTRUCTS RESULT IN VARIABLE CAR SURFACE EXPRESSION AND UPREGULATION OF ACTIVATION MARKERS UPON FVIII STIMULATION | Sarah Scatigna |
| PO018 | USEFULNESS OF PHARMACOKINETICS DATA FOR PERSONALIZED DOSING REGIMENS IN PROPHYLAXIS WITH EXTENDED HALF-LIFE FACTOR. A CASE REPORT | Diana Carneiro-Leão |
| PO019 | DEVELOPMENT OF A PATIENT-REPORTED OUTCOME (PRO) TOOL TO SUPPORT JOINT HEALTH MANAGEMENT FOR PATIENTS WITH HAEMOPHILIA B AGED 8 YEARS AND OLDER | Nisa Khan |
| PO020 | LARGE-SCALE MAPPING OF CD4 T-CELL EPITOPES OF RECOMBINANT FULL LENGTH FVIII IN HEALTHY INDIVIDUALS. | Valeria Porcheddu |
| PO021 | NEARLY PICTURE PERFECT": A MIXED-METHOD STUDY ON EXPERIENCES WITH HEMOPHILIA CARE IN THE NETHERLANDS" | Martijn Brands |
| PO022 | "WHY DOES IT ALWAYS HAVE TO BE HEMOPHILIA FAULT?" | Carola Sella |
| PO023 | A BOY WITH HEMOPHILIA A WITHOUT INHIBITORS IN PROPHYLAXIS WITH EMICIZUMAB IN PORTUGAL: IS HE THE FIRST OF MANY? | Soraia Campaniço |
| PO024 | A PROSPECTIVE, OBSERVATIONAL, ITALIAN STUDY TO ASSESS LONG-TERM EFFECTIVENESS OF DAMOCTOCOG ALFA PEGOL PROPHYLAXIS ON JOINT HEALTH IN ADULTS WITH HAEMOPHILIA A (JOIHA) | Matteo Nicola Dario Di Minno |
| PO025 | A SINGLE CENTRE, OPEN LABEL, PILOT STUDY EVALUATING THE EFFECTS OF HYALURONIC ACID ON PAIN AND FUNCTIONALITY WHEN INJECTED INTO THE ANKLE JOINT IN PATIENTS WITH HAEMOPHILIC ARTHROPATHY | Stephanie Taylor |
| PO026 | ADHERENCE TO PROPHYLAXIS IN MODERATE AND SEVERE HAEMOPHILIA IN A PANDEMIC LIFE SETTING | Fatma Keklik Karadağ |
| PO027 | AN INDIVIDUALIZED APPROACH TO REDUCE INHIBITOR RISK IN PUPS WITH SEVERE HEMOPHILIA A | Susan Halimeh |
| PO028 | ANKLE JOINT IN PEOPLE WITH HAEMOPHILIA: THE ASSOCIATION BETWEEN STRUCTURE, FUNCTION AND PAIN: A CROSS-SECTIONAL STUDY | Valerie-Anne Chantrain |
| PO029 | ANNUALIZED BLEEDING RATE IN HAEMOPHILIA A AND B ON PROPHYLAXIS: ECOLOGICAL STUDY COLOMBIA, 2020. | Jesús Ardila |
| PO030 | ANTI-EMICIZUMAB ANTIBODIES DO NOT CROSS-REACT WITH MIM8 IN VITRO | Roberta Gualtierotti |
| PO031 | APPLICATION OF EMICIZUMAB IN CUBAN PATIENTS WITH HEMOPHILIA A | Dunia Castillo |
| PO032 | AREA UNDER THE CURVE: INDIRECT PRODUCT COMPARISONS BETWEEN FACTOR VIII REPLACEMENT THERAPIES IN HAEMOPHILIA A | Erik Berntorp |
| PO033 | ASSESSING THE IMPACT OF COVID-19 ON PEOPLE WITH HEMOPHILIA (PWH) AGED ≥40 YEARS AND THE HTCS THAT CARE FOR THEM: AN OBSERVATIONAL COHORT STUDY FROM THE ADVANCE WORKING GROUP | Cedric Hermans |
| PO034 | ASSOCIATION BETWEEN ANNUAL BLEEDING EVENTS AND HEALTH-RELATED QUALITY OF LIFE IN ADULTS WITH HAEMOPHILIA A PRESCRIBED PROPHYLAXIS | Lisa Young |
| PO035 | ATHN 16: SAFETY OF COAGULATION FACTOR VIIA (RECOMBINANT)-JNCW FOR THE TREATMENT OF BLEEDING EVENTS IN PATIENTS WITH CONGENITAL HEMOPHILIA A OR B WITH INHIBITORS WITH OR WITHOUT PROPHYLACTIC TREATMENT | Tammuella Chrisentery-Singleton |
| PO036 | BIOEQUIVALENCE (BE) OF MARSTACIMAB PREFILLED PEN (PFP) DEVICE AND PREFILLED SYRINGE (PFS) DEVICE FOLLOWING SUBCUTANEOUS (SC) ADMINISTRATION IN HEALTHY ADULT MALES | Sangeeta Raje |
| PO039 | BONE MINERAL DENSITY IN YOUNG ADULT PATIENTS WITH SEVERE HEMOPHILIA A -A SINGLE-CENTER STUDY | Hristina Ivanova |
| PO040 | BUDGET IMPACT OF RVIII-SINGLECHAIN IN MODERATE AND SEVERE HAEMOPHILIA A TREATMENT IN ITALY | Radovan Tomic |
| PO041 | CANADIAN CLINICAL EXPERIENCE ON SWITCHING FROM OCTOCOG ALFA TO EXTENDED-HALF-LIFE FVIII DAMOCTOCOG ALFA PEGOL IN PATIENTS WITH SEVERE HAEMOPHILIA A | Davide Matino |
| PO042 | CARDIAC SURGERY IN HAEMOPHILIA AN EXPERIENCE OF A CHALLENGING PERIOPERATIVE HEMOSTATIC APPROACH | Cristina Emilia Ursu |
| PO043 | CLEARANCE OF GIROCTOCOGENE FITELPARVOVEC VECTOR DNA IN ADULTS WITH SEVERE HAEMOPHILIA A | Patrick Fogarty |
| PO044 | CLINICAL APPLICATION OF EXTENDED HALF-LIFE PEGYLATED FACTOR VIII IN CHILDREN WITH SEVERE HAEMOPHILIA A | Athina Dettoraki |
| PO045 | CLINICAL OUTCOMES FOLLOWING PROPHYLAXIS WITH RURIOCTOCOG ALFA PEGOL IN PATIENTS WITH HEMOPHILIA A: REAL-WORLD OBSERVATIONAL DATA FROM THE AHEAD INTERNATIONAL STUDY | Margareth Ozelo |
| PO046 | COMPARTMENT SYNDROME MANAGEMENT IN SEVERE HEMOPHILIA A WITH INHIBITORS | Aslı Turgutoğlu Yılmaz |
| PO047 | CURRENT OPINIONS ON THE MANAGEMENT OF ACS IN PEOPLE WITH HEMOPHILIA A: A SURVEY OF THE ADVANCE WORKING GROUP | Robert Klamroth |
| PO048 | DESIGN OF A REAL-WOLRD STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OMFILOCTOCOG ALFA IN PATIENTS RECEIVING PROPHYLACTIC TREATMENT FOR MODERATE OR SEVERE HEMOPHILIA A | Sen Yu |
| PO049 | DOSE SELECTION AND STUDY DESIGN FOR B-LIEVE, A PHASE 1/2 DOSE CONFIRMATION CLINICAL TRIAL OF FLT180A GENE THERAPY FOR PATIENTS WITH HAEMOPHILIA B | Guy Young |
| PO050 | EFFICACY AND SAFETY OF RURIOCTOCOG ALFA PEGOL IN PERIOPERATIVE MANAGEMENT: INTERIM RESULTS FROM AN OPEN-LABEL MULTICENTER CLINICAL TRIAL IN PREVIOUSLY UNTREATED PATIENTS WITH SEVERE HEMOPHILIA A | Flora Peyvandi |
| PO051 | EFFICACY AND SAFETY OF TUROCTOCOG ALFA IN PATIENTS WITH HAEMOPHILIA A REQUIRING SURGICAL PROCEDURES: A FRENCH SINGLE CENTRE RETROSPECTIVE STUDY | Pierre-Olivier Bertho |
| PO052 | EMICIZUMAB AND INITIATION OF TREATMENT IN SEVERE HAEMOPHILIA A CHILDREN: ABOUT A CLINICAL CASE | Hortense Maynadié |
| PO053 | EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH HAEMOPHILIA A (PWHA), AGED ≥50 YEARS, WITH COMORBIDITIES - POOLED DATA FROM FOUR PHASE 3 STUDIES (HAVEN 1, 3, 4, AND STASEY) | Victor Jiménez-Yuste |
| PO054 | EMICIZUMAB PROPHYLAXIS IN SEVERE HAEMOPHILIA A WITHOUT INHIBITORS: OUTCOME AND INDICATIONS. FROM THE UK HAEMOPHILIA CENTRE DOCTORS ORGANISATION | Caroline Wall |
| PO055 | EMICIZUMAB THERAPY IN REAL-LIFE CLINICAL SETTING: DRAMATIC REDUCTION OF BLEEDING RATES IN CHILDREN WITH HEMOPHILIA A WITH INHIBITORS. | Pavel Zharkov |
| PO056 | ESSENTIAL THROMBOCYTHEMIA IN PATIENTS WITH HEMOPHILIA: HIGH THROMBOTIC AND HEMORRHAGIC RISK | Francisco-Jose Lopez-Jaime |
| PO057 | EVALUATION OF CAIS FORMULA IN CHINESE PREVIOUSLY TREATED PATIENTS WITH SEVERE HEMOPHILIA A RECEIVING TUROCTOCOG ALFA | Cai Lisheng |
| PO058 | EXPERIENCE OF IMMUNE TOLERANCE INDUCTION THERAPY FOR HEMOPHILIA A PATIENTS WITH INHIBITORS FROM A SINGLE CENTER IN ALGERIA | Wassila Messadi |
| PO059 | EXPLORING THE TREATMENT EXPERIENCES OF ADOLESCENT AND ADULT PATIENTS WITH HAEMOPHILIA A: EXIT INTERVIEW FINDINGS FROM THE PATHFINDER 8 TRIAL | Meryl Bord |
| PO060 | FIX PRODUCT AT FIRST EXPOSURE IN CHILDREN WITH SEVERE HAEMOPHILIA B BETWEEN 2000-2020: DATA FROM PEDNET | Marijke Van den Berg |
| PO061 | FUNCTIONAL INDEPENDENCE OF ADOLESCENTS WITH HEMOPHILIA FROM A BRAZILIAN HEMOPHILIA TREATMENT CENTER | Ricardo Mesquita Camelo |
| PO062 | FVIII PRODUCT AT FIRST EXPOSURE IN CHILDREN WITH SEVERE HAEMOPHILIA A BETWEEN 2000-2020: DATA FROM PEDNET | Marijke Van den Berg |
| PO063 | GENE THERAPY FOR HAEMOPHILIA: THE EXIGENCY PROGRAMME | Simon Fletcher |
| PO064 | GENETIC AND NON-GENETIC DETERMINANTS OF THE OUTCOME OF IMMUNE TOLERANCE INDUCTION IN PATIENTS WITH HEMOPHILIA A AND INHIBITORS A SYSTEMATIC REVIEW | Ilja Oomen |
| PO065 | HAEMOPHILIA B PATIENTS UNDER RIX-FP PROPHYLAXIS: CLINICAL EXPERIENCE AT HOSPITAL UNIVERSITARIO LA PAZ | Maria Teresa Álvarez Román |
| PO066 | HAEMOPHILIA GENE THERAPY (GT) OUTCOMES: INTEGRATION OF THE HAEMOPHILIA VALUE FRAMEWORK WITH COREHEM | Mark Skinner |
| PO067 | HEALTH-RELATED QUALITY OF LIFE (HRQOL) IMPROVES IN PEOPLE WITH HEMOPHILIA A OR B (PWHA/B) WITH INHIBITORS RECEIVING FITUSIRAN PROPHYLAXIS: RESULTS OF PHASE 3 ATLAS-INH | Claude Négrier |
| PO068 | HEALTH-RELATED QUALITY OF LIFE (HRQOL) OUTCOMES IN PEOPLE WITH HEMOPHILIA A (PWHA) FROM THE A-LONG/ASPIRE STUDIES OF RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFVIIIFC) | Alex Cockerham |
| PO069 | HEMOPHILIA AND CANCER - TWO CASE REPORTS | Wassila Messadi |
| PO070 | HEMOPHILIA HEALTH SERVICES IN LIMITED RESOURCES CLINIC DURING COVID-19 PANDEMIC: MANADO EXPERIENCE | Irene Maryauw |
| PO071 | HEMOPHILIA REGISTRY IN CUBA, DATA OF ALL PATIENTS. | Dunia Castillo |
| PO072 | IDEAL STUDY: A REAL-WORLD ASSESSMENT OF TREATMENT REGIMENS, FACTOR IX TROUGH LEVELS AND CONCENTRATE CONSUMPTION IN HAEMOPHILIA B PATIENTS RECEIVING ALBUTREPENONACOG ALFA IN ITALY | Giancarlo Castaman |
| PO073 | IDENTIFYING PERFORMANCE-BASED OUTCOME MEASURES OF PHYSICAL FUNCTION IN PEOPLE WITH HAEMOPHILIA (IPOP) | David Stephensen |
| PO074 | ILLNESS PERCEPTIONS RELATED TO JOINT PAIN IN ADULT PEOPLE WITH HEMOPHILIA. | Anthe Foubert |
| PO075 | IMPACT OF EXTENDED HALF-LIFE FACTORS ON THE QUALITY OF LIFE OF PATIENTS WITH HEMOPHILIA B AND CAREGIVERS. EXPERIENCE IN OUR CENTER. | Jose Carlos De La Rosa Garcia |
| PO076 | IMPACT OF RFVIII-SC ON JOINT HEALTH-CLINICAL CASE REPORT | Olga Benitez Hidalgo |
| PO077 | IMPACT OF VALOCTOCOGENE ROXAPARVOVEC GENE TRANSFER FOR SEVERE HAEMOPHILIA A ON HEALTH-RELATED QUALITY OF LIFE | Brian O'Mahony |
| PO078 | INHERETED HEMOPHILIA WITH INHIBITORS TO FACTORS VIII AND IX | Tatsiana Talako |
| PO079 | INNOVATIVE BREAKTHROUGH TREATMENT, THE FINANCING OF EDUCATIONAL PROGRAMMES IS THE RESPONSIBILITY OF MANUFACTURERS, A FIRST IN FRANCE WITH THE EXAMPLE OF EMICIZUMAB | Thomas Sannié |
| PO080 | INTERIM BASELINE DATA ON THE 48-MONTH PROSPECTIVE, OBSERVATIONAL A-MORE STUDY EVALUATING LONG-TERM EFFECTIVENESS OF RFVIIIFC ON JOINT HEALTH | Jan Astermark |
| PO081 | INTERIM DATA FROM A CHART REVIEW STUDY OF PATIENTS WITH HAEMOPHILIA A WITH INHIBITORS TREATED WITH RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFVIIIFC) FOR IMMUNE TOLERANCE INDUCTION | Robert Klamroth |
| PO082 | INVASIVE PROCEDURES IN PATIENTS WITH HAEMOPHILIA ON EMICIZUMAB PROPHYLAXIS: REAL-WORLD CLINICAL EXPERIENCE IN SLOVENIA | Karla Rener |
| PO083 | JOINT HEALTH IN YOUNG ADULTS WITH SEVERE HAEMOPHILIA RECEIVING PRIMARY PROPHYLAXIS: AN INSIGHT FROM THE CHESS II EUROPEAN STUDY | Sharmila Kar |
| PO084 | JOINT HEALTH STATUS ASSESSMENT OF HAEMOPHILIA PATIENTS NOT TREATED WITH PROPHYLAXIS | Bolívar Luis Díaz Jordán |
| PO085 | JOINT STATUS OF PATIENTS WITH NON-SEVERE HEMOPHILIA A | Anne-Fleur Zwagemaker |
| PO086 | LIVING WITH HAEMOPHILIA A IN PORTUGAL: PRELIMINARY RESULTS OF A QUALITATIVE MARKET RESEARCH STUDY | Susana Nobre Fernandes |
| PO087 | LONG TERM FOLLOW UP OF LOW DOSE PROPHYLAXIS IN TUNISIAN CHILDREN WITH HAEMOPHILIA | Rabeb Jaied |
| PO088 | LONG-TERM EFFECT OF TUROCTOCOG ALFA PEGOL ON TREATMENT SATISFACTION IN PREVIOUSLY TREATED PATIENTS WITH HAEMOPHILIA A: RESULTS FROM PATHFINDER8 | Azusa Nagao |
| PO089 | MAJOR ORTHOPEDIC SURGERIES USING EXTENDED HALF-LIFE (EHL) COAGULATION REPLACEMENT FACTORS: THE EXPERIENCE OF A GREEK COMPREHENSIVE HAEMOPHILIA TREATMENT CENTER (CHTC) | Anna Kouramba |
| PO090 | MANAGEMENT OF ACQUIRED HEMOPHILIA A:REVIEW OF OUR EXPERIENCE OF THE LAST 15 YEARS | Gianluca Sottilotta |
| PO091 | MANAGEMENT OF BREAKTHROUGH BLEEDS DURING CONCIZUMAB PROPHYLAXIS IN PATIENTS WITH HAEMOPHILIA A/B WITH AND WITHOUT INHIBITORS IN PHASE 3 CLINICAL TRIALS | Jan Astermark |
| PO092 | MANAGEMENT OF FACTOR XI DEFICIENCY TREATMENT IN A CASE WITH CRANIOPHARYNGIOMA | Serap Karaman |
| PO093 | MANAGEMENT OF INTRACRANIAL HEMORRHAGE IN HEMOPHILIA A PATIENTS | Wassila Messadi |
| PO094 | MEDICAL AND SOCIO-PSYCHOLOGICAL EFFECTS OF THE PANDEMIC ON PATIENTS WITH HEREDITER BLEEDING DISORDERS AND THEIR TREATERS | Bulent Zulfikar |
| PO095 | MINOR SURGERIES IN PATIENTS RECEIVING PROPHYLAXIS WITH CONCIZUMAB: EXPERIENCE IN OUR CENTER | Ana-Maria Mena-Santano |
| PO096 | MONITORING OF EMICIZUMAB USING A PATIENT REGISTRY | Geertje Goedhart |
| PO097 | MOROCTOCOG ALFA (AF-CC) PROPHYLAXIS AND TREATMENT OF BLEEDING EPISODES IN PREVIOUSLY TREATED PATIENTS WITH MODERATE OR SEVERE HEMOPHILIA A IN INDIA | Damien Simoneau |
| PO098 | MULTIPLE-YEAR DURABILITY DATA FROM A PHASE 2B TRIAL OF GENE THERAPY WITH ETRANACOGENE DEZAPARVOVEC IN PATIENTS WITH HEMOPHILIA B | Esteban Gomez |
| PO099 | PAIN RELIEF WITH EPTACOG BETA IN HEMOPHILIA PATIENTS WITH INHIBITORS | Cédric Hermans |
| PO100 | PATIENT-ORIENTED APPROACH IN THE MANAGEMENT OF HEMOPHILIA; A MULTICENTER SURVEY ON INJECTIONS WITHOUT A VIAL IN PLACE | Haluk Zulfikar |
| PO101 | PERIOPERATIVE MANAGEMENT AND TROMBOELASTOMETRY MONITORING IN A CASE OF HEMOPHILIA A WITH INHIBITOR ON EMIZICUMAB PROPHYLAXIS | Abel Dos Santos Ortas |
| PO102 | PERIOPERATIVE MANAGEMENT IN NON-SEVERE HEMOPHILIA PATIENTS | Carmen Rodríguez Lefler |
| PO103 | PERIOPERATIVE USE OF EXTENDED HALF-LIFE (EHL) FVIII AND FIX CONCENTRATES IN CHILDREN WITH HAEMOPHILIA A AND B | Aikaterini Michalopoulou |
| PO104 | PHARMACOKINETIC MODEL-BASED DOSE SETTING FOR PROPHYLAXIS WITH FACTOR IX PRODUCTS IN SEVERE HAEMOPHILIA B | Karen Pinachyan |
| PO105 | PHARMACOKINETIC-GUIDED PROPHYLAXIS WITH RECOMBINANT ANTIHEMOPHILIC FACTOR IMPROVES BLEEDING RATES IN PATIENTS WITH MODERATE HEMOPHILIA: REAL-WORLD OBSERVATIONAL DATA FROM THE AHEAD GERMAN STUDY | Robert Klamroth |
| PO106 | PK-GUIDED PROPHYLAXIS VERSUS STANDARD PROPHYLAXIS REGIMENS IN SEVERE HEMOPHILIA | Daniel Kraemmer |
| PO107 | PRESENTATION OF 5 CASES WITH ACQUIRED HEMOPHILIA A TREATED AT THE CLINIC OF HEMATOLOGY IN SKOPJE | Svetlana Stankovikj |
| PO108 | PREVIOUSLY UNTREATED PATIENTS IN GERMANY 2017 - 2021 A CROSS-SECTIONAL ANALYSIS OF 249 PATIENTS FROM THE GEPHARD COHORT | Christoph Bidlingmaier |
| PO109 | PROPHYLAXIS AND ZERO BLEED FOR ALL ADULT PATIENTS WITH SEVERE HEMOPHILIA: AN ACHIEVABLE AMBITION WITH NEW TREATMENT OPTIONS | Cedric Hermans |
| PO110 | PROPHYLAXIS WITH DAMOCTOCOG ALFA PEGOL: REAL WORLD USAGE AND EFFECTIVENESS IN PATIENTS WITH HEMOPHILIA A OF A PORTUGUESE HEMOPHILIA REFERENCE CENTRE | Soraia Campaniço |
| PO111 | PROTECTIVE AND RISK FACTOR FOR PERIODONTAL DISEASES IN A BLEEDING DISORDERS POPULATION | Laura Isidro |
| PO112 | QUALITATIVE RESEARCH EVALUATING PATIENT PREFERENCE FOR HAEMOPHILIA THERAPY | Wolfgang Miesbach |
| PO113 | REAL WORLD DATA ON BLEEDING PATTERN IN A COHORT OF HEMOPHILIA A PATIENTS TREATED WITH EMICIZUMAB | Sarina Levy-Mendelovich |
| PO114 | REAL-WORLD DATA ON EMICIZUMAB PROPHYLAXIS IN THE MILAN COHORT: A SINGLE-CENTER EXPERIENCE | Sara Arcudi |
| PO115 | RELATIONSHIP OF FUNCTIONAL FIBRINOGEN WITH CLOT FIRMNESS AND JOINT HEALTH IN PATIENTS WITH SEVERE HEMOPHILIA | Paula Acuña |
| PO116 | REMOTE COORDINATION OF THE MULTIDISCIPLINARY HAEMOPHILIA TEAM WITH SKELETAL IMAGING SUPPORT. BEYOND THE PANDEMIC | A.Patricia Nally |
| PO117 | RIX-FP PROPHYLAXIS IN PATIENTS WITH HAEMOPHILIA B: REAL-WORLD EVIDENCE FROM A SPANISH REFERENCE CENTER | Olga Benítez Hidalgo |
| PO118 | RVIII-SINGLECHAIN FOR TREATMENT OF PREVIOUSLY UNTREATED PATIENTS WITH SEVERE HAEMOPHILIA A: A SINGLE-CENTRE EXPERIENCE | Susana Nobre Fernandes |
| PO119 | SAFE AND EFFICACIOUS USE OF EFMOROCTOCOG ALFA IN A PREGNANT WOMAN WITH HAEMOPHILIA A. | David Quinn |
| PO120 | SAFETY AND EFFECTIVENESS OF RECOMBINANT B-DOMAINDELETED PORCINE-SEQUENCE FACTOR VIII FOR ACQUIRED HEMOPHILIA A IN A REAL-WORLD SETTING | Wolfgang Miesbach |
| PO121 | SAFETY AND EFFICACY OF DAMOCTOCOG ALFA PEGOL PROPHYLAXIS IN PATIENTS WITH SEVERE HAEMOPHILIA A: INTERIM RESULTS OF A POST-MARKETING, INTERVENTIONAL STUDY | Pål Andrè Holme |
| PO122 | SAFETY AND EFFICACY OF MARSTACIMAB FOR PREVENTION OF BLEEDING EPISODES IN PAEDIATRIC PATIENTS WITH SEVERE HAEMOPHILIA A OR MODERATELY SEVERE TO SEVERE HAEMOPHILIA B WITH OR WITHOUT INHIBITORS | John Teeter |
| PO123 | SAFETY AND EFFICACY OF NONACOG ALFA PROPHYLAXIS AND TREATMENT OF BLEEDING EPISODES IN PREVIOUSLY TREATED PATIENTS WITH MODERATELY SEVERE OR SEVERE HEMOPHILIA B IN INDIA | Damien Simoneau |
| PO124 | SECOND INTERIM ANALYSIS OF THE PHASE IV HEM-POWR STUDY EVALUATING THE REAL-WORLD EFFECTIVENESS AND SAFETY OF DAMOCTOCOG ALFA PEGOL IN PREVIOUSLY TREATED PATIENTS WITH HAEMOPHILIA A | Mark Reding |
| PO125 | SEVERE HAEMOPHILIA A AND FACTOR V LEIDEN: A CASE REPORT | Catarina Almeida |
| PO126 | SHOCK INDEX AS HEMARTHROSIS MARKER IN HEMOPHILIA PATIENTS IN COLOMBIA: A PROGNOSTIC APPROACH | Mario-Miguel Barbosa |
| PO127 | SPINAL EPIDURAL HEMATOMA IN A SEVERE HEMOPHILIA A WITH A HIGH TITER INHIBITOR | Selin Aytac |
| PO129 | SURGERIES AND DIAGNOSTIC PROCEDURES IN HAEMOPHILIA PATIENTS ON CONCIZUMAB PROPHYLAXIS IN PHASE 2 CLINICAL TRIALS | Allison Wheeler |
| PO130 | SURGICAL MANAGEMENT IN PATIENT WITH SEVERE HAEMOPHILIA B RECEIVING RFIX-FC: CASE REPORT | Olga Benitez Hidalgo |
| PO131 | SYSTEMATIC JOINT EXAMINATION IN PATIENTS WITH HAEMOPHILIA A IN FRANCE: INTERIM BASELINE RESULTS FROM THE A-MOVE STUDY | Brigitte Pan-Petesch |
| PO132 | THE CLINICAL AND ECONOMIC IMPACT OF RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFVIIIFC) ON LONG-TERM JOINT HEALTH IN PEOPLE WITH HEMOPHILIA A (PWHA) | Katharine Batt |
| PO133 | THE CLINICAL PHENOTYPE OF PATIENTS WITH NON-SEVERE HEMOPHILIA A AND B | F.R. Kloosterman |
| PO134 | THE HEM-CORE SURVEY: PSYCHOLOGICAL REACTION OF HEMOPHILIA PATIENTS DURING COVID-19 | Gianluca Sottilotta |
| PO135 | THE IMPACT OF COVID19 PANDEMIC ON HEMOPHILIA CARE: EXPERIENCE OF A SINGLE PEDIATRIC TREATMENT CENTER | Maria Vousvouki |
| PO136 | THE IMPACT OF SEVERE HAEMOPHILIA ON EVERYDAY LIFE AMONG ADULTS: REPORTS FROM THE CHESS II STUDY ACROSS EUROPE | Sharmila Kar |
| PO137 | THE TOOL STUDY. PRELIMINARY RESULTS FROM A MULTICENTER COHORT OF HAEMOPHILIA A PATIENTS SWITCHING TO AN EXTENDED HALF-LIFE AGENT. | Helen Pergantou |
| PO138 | THE USE OF PAEDIATRIC PROMIS® ITEM BANKS IN DUTCH BOYS WITH HAEMOPHILIA | Lorynn Teela |
| PO139 | THE WORLD FEDERATION OF HEMOPHILIA GENE THERAPY REGISTRY A GLOBAL RESOURCE FOR THE LONG-TERM FOLLOW-UP OF HEMOPHILIA PATIENTS TREATED WITH GENE THERAPY | Mayss Naccache |
| PO140 | TRANSITION READINESS AMONG ADOLESCENTS AND YOUNG ADULTS WITH HAEMOPHILIA IN THE NETHERLANDS | Martijn Brands |
| PO141 | TREATMENT SATISFACTION SURVEY FOR HEMOPHILIA A IN ADULT PATIENTS IN RUSSIA | Nadezhda Ivanovna Zozulya |
| PO142 | UNMET NEEDS IN HEMOPHILIA B: PERSPECTIVES FROM PEOPLE LIVING WITH HEMOPHILIA B, HEALTHCARE PROFESSIONALS AND THE HEALTHCARE INDUSTRY | Karen Pinachyan |
| PO143 | UPDATE FROM THE PHASE 3 HOPE-B GENE THERAPY TRIAL: STABLE STEADY-STATE EFFICACY AND SAFETY OF ETRANACOGENE DEZAPARVOVEC IN ADULTS WITH SEVERE OR MODERATELY SEVERE HEMOPHILIA B | Wolfgang Miesbach |
| PO144 | USE OF SUSOCTOCOG ALFA AS POST-OPERATIVE BLEEDING PREVENTION IN A PATIENT WITH ACQUIRED HEMOPHILIA A AND ANTI-PORCINE FVIII ANTIBODIES: A CASE REPORT | Marco Bardetta |
| PO145 | USING COMBINED LIMITED SAMPLING STRATEGIES TO MAKE PHARMACOKINETIC-GUIDED SWITCHING BETWEEN FACTOR VIII CONCENTRATES MORE EFFICIENT | Laura Bukkems |
| PO146 | VALOCTOCOGENE ROXAPARVOVEC GENE TRANSFER IN PARTICIPANTS WITH HIV | Margaret Ragni |
| PO147 | WHEN A BRAIN HEMORRHAGE REVEALS OTHER PROBLEMS | Filipa Martins Pereira |
| PO148 | ALLOANTIBODIES IN VON WILLEBRAND DISEASE IN SOUTH OF TUNISIA | Rahma Mallek |
| PO149 | DIAGNOSIS OF VON WILLEBRAND DISEASE IN RUSSIA: EXPERIENCE IN CENTRALIZED DIAGNOSTICS. | Aleksandr Poletaev |
| PO150 | ESTABLISHMENT OF REFERENCE INTERVALS FOR THE VON WILLEBRAND FACTOR ANTIGEN IN ALGERIAN ADULTS ACCORDING TO BLOOD GROUP ABO | Malika BELKACEMI |
| PO151 | PLATELET AGGREGATION ABNORMALITIES IN PATIENTS VON WILLEBRAND DISEASE TYPE 2B. | Yuly Paola Martínez |
| PO152 | VON WILLEBRAND DISEASE (VWD) INCIDENCE AMONG PATIENTS WITH BLEEDING MANIFESTATIONS FROM MULTI HAEMOPHILIA TREATMENT CENTERS (HTCS) IN EGYPT: DATA FROM VWD REGISTRY | Sonia Adolf |
| PO153 | VWF GENE PATHOGENIC VARIANTS SPECTRUM IN RUSSIAN PATIENTS WITH VON WILLEBRAND DISEASE | Daria Chernetskaya |
| PO154 | A VERY COMPLICATED COURSE AFTER VAGINAL DELIVERY IN TYPE 3 VON WILLEBRAND DISEASE WITH ALLOANTIBODIES TO VON WILLEBRAND FACTOR AND FACTOR VIII | Lize van Vulpen |
| PO155 | ACQUIRED VON WILLEBRAND DISEASE AND CHRONIC LYMPHOCYTIC LEUKAEMIA: REMISSION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION | Francisco-Jose Lopez-Jaime |
| PO156 | AN UNUSUAL CASE OF A YOUNG WOMAN WITH TYPE 2A VON WILLEBRAND DISEASE DEVELOPING ANTI VWF ANTIBODIES | Birgit Frotscher |
| PO157 | ASSESSMENT OF PATIENTS WITH VON WILLEBRAND DISEASE WITH ISTH-BAT IN SOUTHERN TUNISIA | Rahma Mallek |
| PO158 | EFFICACY AND SAFETY OF HIGH RATIO HVWF/FVIII CONCENTRATE (VONCENTO®) FOR THE TREATMENT OF BLEEDING EPISODES IN PATIENTS WITH VON WILLEBRAND DISEASE: THE OPALE FRENCH EXPERIENCE | Roseline dOiron |
| PO159 | LIFE THREATENING BLEEDINGS IN VON WILLEBRAND DISEASE IN SOUTHERN TUNISIA | Rahma Mallek |
| PO160 | RECURRENT EPISTAXIS IN PATIENT WITH ACQURED VON WILLEBRAND SYNDROME AND MONOCLONAL GAMMOPATHY OF UNDETERMINATED SIGNIFICANCE | Ana Rosa Carranco Falcón |
| PO161 | THE PROGNOSTIC VALUE OF THE APPLICATION OF THE ISTH-BAT CLINICAL SCORE IN VON WILLEBRAND DISEASE : SERIES OF 20 PATIENTS FOLLOWED AT THE UNIVERSITY HOSPITAL OF ORAN | Reda Messaoudi |
| PO162 | TREATMENT COMPLIANCE IN PATIENTS WITH VON WILLEBRAND'S DISEASE | Nadezhda Ivanovna Zozulya |
| PO163 | TREATMENT WITH A PLASMA-DERIVED VON WILLEBRAND FACTOR (VWF) ALMOST DEVOID OF FACTOR VIII IN ELDERLY PATIENTS WITH VON WILLEBRAND DISEASE (VWD): A POOLED ANALYSIS | Jenny Goudemand |
| PO164 | VONICOG ALFA IN PREGNANCY IS SAFE AND EFFICACIOUS | David Quinn |
| PO165 | A SUCCESSFUL 11-YEAR TREATMENT WITH TOPICAL PLASMINOGEN, SURGERY AND PROSTHETIC EYE FITTING IN SEVERE LIGNEOUS CONJUNCTIVITIS | Antonella Coretti |
| PO166 | ACCESS TO PREGNANCY FOR WOMEN WITH TYPE 1 GLANZMANN'S THROMBASTHENIA: A SYSTEMATIC APPROACH | Guillaume Morelle |
| PO167 | ACCIDENTAL DISCOVERY OF AN UNUSUAL CONSTITUTIONAL DYSFIBRINOGENEMIA: LONGMONT FIBRINOGEN | Ahlem Raissi |
| PO168 | ACQUIRED FACTOR V INHIBITOR ASSOCIATED TO CHRONIC LYMPHATIC LEUKAEMIA (CLL). A CASE REPORT. | Alberto Porro Camarero |
| PO169 | ACQUIRED HAEMOPHILIA A ASSOCIATED TO POSTPARTUM PERIOD: A CASE REPORT OF A DELAYED DIAGNOSIS | Rebeca Jurado Tapiador |
| PO170 | APPLICATION OF THE ISTH-BAT HEMORRHAGIC SCORE IN CONSTITUTIONAL BLEEDING DISORDERS | Reda Messaoudi |
| PO171 | CLINICAL PHENOTYPE IN PATIENTS WITH HEREDITARY FACTOR XII DEFICIENCY | Nadezhda Zozulya |
| PO172 | COEXISTENCE OF PLATELET GLYCOPROTEIN IV DEFICIENCY AND VON WILLEBRAND DISEASE: UNIQUE CLINICAL AND MOLECULAR CHARACTERISTICS. | Mohamed Elshinawy |
| PO173 | EPIDEMIOLOGY AND CHARACTERISTICS OF SEVERE RARE HEREDITARY BLEEDING DISORDERS AT A REFERENCE CENTER IN SPAIN | María Fernanda Martínez García |
| PO174 | EVALUATION OF HEMORRHAGIC OR THROMBOTIC PROFILE IN PATIENTS WITH DYSFIBRINOGENEMIA | Virginie Barbay |
| PO175 | FACTOR V MUTATION PREVIOUSLY NOT DESCRIBED A CASE REPORT | Liliana Fonseca |
| PO176 | FEMALE PATIENTS WITH BLEEDING DISORDERS: SINGLE CENTER RESULTS | Canan Albayrak |
| PO177 | FIVE PATIENTS WITH COMBINED FACTOR V AND FACTOR VIII DEFICIENCY: EXPERIENCE OF TWO CENTERS IN SAMSUN-TURKEY | Canan Albayrak |
| PO178 | INHERITED (HYPO)DYSFIBRINOGENEMIA AND THROMBOSIS IN TWO FAMILIES CAUSED BY THE SAME NOVEL GLY318SER SUBSTITUTION IN THE FIBRINOGEN GAMMA CHAIN | Eugénia Cruz |
| PO179 | INVASIVE MAJOR SURGERY IN PATIENTS WITH FXII DEFICIENCY TWO CENTERS EXPERIENCE | Ines Vaide |
| PO180 | LONGITUDINAL COMPARATIVE STUDY OF CHILDREN WITH IMMUNE THROMBOCYTOPENIA (ITP): A SINGLE CENTRE EXPERIENCE | Aikaterini Michalopoulou |
| PO181 | MENSTRUAL PROBLEMS IN CHRONIC IMMUNE THROMBOCYTOPENIA: A MONTHLY CHALLENGE - A COHORT STUDY AND REVIEW | Wobke Van Dijk |
| PO182 | NOVEL VARIANTS IN ETV6 AND FYB1 GENES: TWO CHILDREN WITH RARE INHERITED THROMBOCYTOPENIA | Veysel Gök |
| PO183 | PREDICTION VALUE OF PEDIATRIC BLEEDING QUESTIONNAIRE (PBQ) FOR CHILDREN WITH DIFFERENT BLEEDING DISODERS | Tatyana Yafoshkina |
| PO184 | RETROSPECTIVE COMPARATIVE ANALYSIS OF HEMORRHAGIC SYNDROME SEVERITY IN CHILDREN WITH GLANZMANN THROMBASTHENIA AND OTHER BLEEDING DISORDERS | Maria Ustinova |
| PO185 | SEVERE FACTOR XI DEFICIENCY A CASE REPORT | Liliana Fonseca |
| PO186 | THROMBOTIC EVENTS IN CHILDREN AND ADOLESCENTS DURING THE COVID-19 PANDEMIC PERIOD. DATA OF A REFERENCE CENTER IN GREECE | Loukia Ioannidou |
| PO187 | WEAKENING OF THE PROCOAGULANT ACTIVITY OF PLATELETS AND THE SEVERITY OF HEMORRHAGIC SYNDROME IN CHILDREN WITH INHERITED THROMBOCYTOPENIAS | Dmitrii Polokhov |
| PO188 | EFFECTS OF MULTIMODAL EXERCISES PROGRAM ON BALANCE, FUNCTIONALITY, RISK OF FALLS AND STRENGTH IN PEOPLE WITH HAEMOPHILIA | Ana Chimeno-Hernández |
| PO189 | IMMERSIVE MOVEMENT VISUALIZATION IN PATIENTS WITH HEMOPHILIC ARTHROPATHY: A POSSIBLE THERAPEUTIC ALTERNATIVE IN HEMOPHILIA? | Roberto Ucero-Lozano |
| PO190 | MAY SELF-INDUCED MYOFASCIAL RELEASE BE SAFE AND EFFECTIVE IN PATIENTS WITH HEMOPHILIC ANKLE ARTHROPATHY? | Elena Donoso-Úbeda |
| PO191 | PHYSIOTHERAPEUTIC EVALUATION OF JOINT HEALTH OF HEMOPHILIAC PATIENTS THROUGH HJHS, REFERRED TO RADIOACTIVE SYNOVECTOMY BRAZIL EXPERIENCE. | Fernando Zikan |
| PO192 | PHYSIOTHERAPY, HEMOPHILIA AND INTERNATIONAL CLASSIFICATION OF FUNCTIONALITY - DO WE HAVE SCIENTIFIC EVIDENCE AVAILABLE? | Fernando Zikan |
| PO193 | SELF-INDUCED MYOFASCIAL RELEASE: EFFECTIVENESS IN THE HOME APPROACH TO HEMOPHILIC KNEE ARTHROPATHY. | Raúl Pérez-Llanes |
| PO194 | THE HISTORICAL EVOLUTION OF PHYSIOTHERAPY FOR THE MULTIDISCIPLINARY MANAGEMENT OF PATIENTS WITH HAEMOPHILIA (PWH) | Valentina Begnozzi |
| PO195 | EHCUCATE: DEVELOPING AN ENGAGING AND ACCESSIBLE NOVEL THERAPIES EDUCATIONAL APP | Fiona Robinson |
| PO196 | REHABILITATION OF PATIENTS WITH BLEEDING DISORDERS BY MULTIDISCIPLINARY CARE TEAM IN ESTONIA IN KURESSAARE | Ines Vaide |
| PO197 | VIRTUAL REALITY: INCREASING EMPOWERMENT IN THE SELF-TREATMENT OF PEOPLE WITH HEMOPHILIA WITH NEW TECHNOLOGIES | Amparo Santamaria |
| PO198 | WORDS IN HEMOPHILIA: A PROJECT FOR A BETTER PATIENT ENGAGEMENT | Serena Barello |
